The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy

Dysphagia Clinical Trial

— PhINEST  

Official title:

The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy: a Prospective, Multi-site, Randomised, Sham-controlled, Single-blind (Outcome Assessor-blinded) Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03840395
• Other study ID #: AHE-06
• Status: Recruiting
• Phase: N/A
• Start date: June 17, 2019
• Est. completion date: December 2025

Study information

• Verified date: September 2023
• Source: Phagenesis Ltd.
• Contact: Satish Mistry, PhD
• Phone: +44 161 820 4525
• Email: clinical[@]phagenesis.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-site, randomised, sham-controlled, single-blind (outcome assessor-blinded) study designed to assess the effects of Pharyngeal Electrical Stimulation (PES) (using Phagenyx®) for the treatment of oropharyngeal dysphagia after invasive mechanical ventilation (of any duration) by means of naso or oro-tracheal tube in critically ill intensive care unit (ICU) patients.

Description:

The PhINEST study is designed to assess the effects of Pharyngeal Electrical Stimulation (PES) (using Phagenyx®) for treatment of oropharyngeal dysphagia after invasive mechanical ventilation (of any duration) by means of naso or oro-tracheal tube in critically ill intensive care unit (ICU) patients.

The main clinical outcomes assessing unsafe swallows and dysphagia severity will be measured using the gold standard, i.e. Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and bedside swallowing assessments on day 2* after completion of final PES treatment.

Randomisation will be on a 1:1 basis at each site stratified for neurological vs. non-neurological reason for admission (Acute Physiology and Chronic Health Evaluation (APACHE) IV diagnostic group). Patients will receive either PES/sham treatment in addition to standard supportive ICU care and standard of care treatments for dysphagia. Administration of all protocol-specific assessments will be conducted by personnel blinded to treatment assignment.

The study will follow an adaptive population enrichment and sample size re-estimation (SSR) design with one interim look. The study will start with a planned sample size of 200 patients and a maximum (evaluable) sample size of 360. Interim analysis after completion of approximately 140 (evaluable) patients will determine:

I. futility stopping; OR II. sample size increase for the overall sampled population; OR III. Enrichment based on the composite primary endpoint by pre-defined subgroups (neurological vs. non-neurological reason for admission according to APACHE IV diagnostic groups). Thus enrollment of patients in the non-performing sub-group will be stopped at the interim while a sample-size re-estimation based on conditional power will be carried out for the other sub-group.

All interim decisions will be based on conditional power which for the Finkelstein-Schoenfeld (FS)-statistic will need to be computed via Monte-Carlo simulations.

Up to thirty (30) investigational sites across Europe are planned to participate in this study which is expected to last 48 months from first patient first visit to last patient last visit. Patients will be assessed at the following intervals: screening, baseline, on day 2* after completion of final study treatment, 7 ± 1 days after final study treatment and 14 ± 1 days after final study treatment (or hospital discharge if earlier). 30-day and 90-day mortality data will also be collected from the patients medical notes/electronic heath records/telephone call (no additional visit required).

*The day two (FU1) visit is to be conducted on the second day (~24hrs) following final PES treatment but may, under certain circumstances, be conducted upon/by the fourth day (~60 hrs) following final study treatment in instances where the final study treatment is delivered on late Friday and where FEES assessment is only possible early on Monday as no weekend FEES service is available at the investigation site.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 360
• Est. completion date: December 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Pre-screening Inclusion Criteria:

All of the following criteria must be met for inclusion:

• Age = 18 = 85,

• Emergency ICU admission (unplanned admission),

• Recent extubation following invasive mechanical ventilation (of any length of time) by means of endotracheal tube,

• Presence of post-extubation dysphagia as determined by the participating Sites' Standard Of Care (SOC).

Screening / Enrolment Criteria:

To be eligible for enrolment in this study, an individual must meet all of the following additional criteria:

• Presence of written informed consent according to respective national guidelines,

• Dysphagia severity status classified according to PAS on FEES assessment as 'aspiration' (PAS score = 6),

• Richmond Agitation and Sedation Scale (RASS) score within the range of -1 to +2 (i.e. if score equals -2, -3, -4 or +3, +4, patient is excluded).

Randomisation Inclusion Criteria (post-consent)

The following additional criteria must be met for randomisation:

• Successful placement and subjective tolerance of the Phagenyx® Catheter within 2 days of extubation.(post consent)

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from enrolment in this study:

• Nasal anatomical deformity, nasal airway obstruction; patient who have had recent oral, nasal or oesophageal surgery or patient presenting with facial and/or cranial fractures or any other circumstance (e.g. history of oesophageal perforation, stricture, pouch, resection or rupture) where the placement of a standard nasogastric feeding tube (NGT) would be deemed unsafe,

• Cardiac or respiratory condition that might render the insertion (placement) of a catheter into the throat unsafe,

• Permanently implanted electrical devices,

• Are pregnant (pregnancy test) or known lactating women,

• Have non-neurogenic dysphagia (e.g. Cancer-related),

• Any prior tracheostomy,

• Patients who at the time of extubation have any treatment limitation (i.e., palliative care, life expectancy less than 48 hours, or are moribund), that prevents or would prevent compliance with study-specific instructions or procedures (as judged by the investigator),

• Severe cognitive impairment or other reasons that prevents compliance with study-specific instructions or procedures (as judged by the investigator),

• Previous history of dysphagia of any origin,

• Pre-existing tube feeding of any form (e.g. percutaneous gastric/enteral feeding tube related to previous injuries indicating previous dysphagia. NGTs are not an exclusion criterion),

• Participation in another interventional study (medicinal or device) that could influence the outcomes of PES,

• Treatment of dysphagia with other forms of electrical stimulation.

Related Conditions & MeSH terms

• Deglutition Disorders
• Dysphagia

Intervention

Device:
• Pharyngeal Electrical Stimulation (PES)
The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.

Locations

Country	Name	City	State
Austria	Medizinische Universität Innsbruck - Medizinische Universität Innsbruck	Innsbruck
Austria	Medizinische Universität Innsbruck - Universitätsklinik für Anästhesie und Intensivmedizin	Innsbruck
Austria	Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin I	Innsbruck
Finland	Helsinki University Hospital Perioperative, Intensive Care and Pain Medicine	Helsinki
Finland	Oulu University Hospital	Oulu
Germany	Universitätsklinikum Hamburg-Eppendorf - Klinik für Intensivmedizin	Hamburg
Switzerland	University Clinic for Intensive Medicine, Inselspital	Bern

Sponsors (3)

Lead Sponsor	Collaborator
Phagenesis Ltd.	Cytel Inc., NAMSA

Countries where clinical trial is conducted

Austria,  Finland,  Germany,  Switzerland, 

References & Publications (1)

Schefold JC, Backlund M, Ala-Kokko T, Zuercher P, Mukherjee R, Mistry S, Mayer SA, Dziewas R, Bakker J, Jakob SM. The PhINEST study - Pharyngeal ICU Novel Electrical Stimulation Therapy: Study protocol of a prospective, multi-site, randomized, sham-controlled, single-blind (outcome assessor-blinded) study. Medicine (Baltimore). 2020 Mar;99(11):e19503. doi: 10.1097/MD.0000000000019503. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Effectiveness of Phagenyx® treatment in reducing (dysphagia) secretion severity.	Exploratory analysis of changes in secretion severity (severity of dysphagia) between FEES assessments measured by an Independent FEES Review Committee (IFRC) using the Murray Secretion Severity Rating Scale (SSS).; The SSS is a simple, easy-to-use, 4-point scale that can systematically rate the graduation of accumulated secretions within the pharyngolarynx and trachea during FEES.; 0. Normal; Mild; Moderate; Severe	Day 2 (~24 to ~60 hours) after the final Phagenyx® treatment
Other	Effectiveness of Phagenyx® treatment in improving swallowing safety and efficiency - PAS scores	Exploratory analysis of changes in swallowing safety and efficiency (severity of dysphagia) between FEES assessments measured by an IFRC based on worst PAS score for each bolus consistency (semi-solid and solid) for each patient during FEES assessment converted to a dichotomised ordinal response of non-aspirator (PAS 1-5) or aspirator (PAS 6-8).	Day 2 (~24 to ~60 hours) after the final Phagenyx® treatment
Other	Effectiveness of Phagenyx® treatment in reducing bolus residue	Exploratory analysis of changes in bolus residue (severity of dysphagia) between FEES assessments measured by an IFRC using the Yale Pharyngeal Residue Severity Rating Scale (YRS).; The YRS is a reliable, validated, anatomically defined, and image-based five-point ordinal rating scale to determine severity of post-swallow pharyngeal residue location (vallecula and pyriform sinus) and amount (i. none, ii. trace, iii. mild, iv. moderate, and v. severe) during FEES.	Day 2 (~24 to ~60 hours) after the final Phagenyx® treatment
Other	Effectiveness of Phagenyx® treatment in reducing global dysphagia severity	Exploratory analysis of changes in severity of dysphagia between FEES assessments measured by an IFRC using the Global Dysphagia Severity Rating Scale (GDS).; The GDS is a simple, easy-to-use, 4-point scale developed to systematically rate the severity of dysphagia during FEES.; 0. No relevant dysphagia; Mild dysphagia: Premature spillage and/or residues, but no penetration/aspiration events.; Moderate dysphagia: Penetration/aspiration events with one consistency.; Severe dysphagia: Penetration/aspiration events with two or more consistencies.	Day 2 (~24 to ~60 hours) after the final Phagenyx® treatment
Other	Effectiveness of Phagenyx® treatment on time from extubation to hospital discharge	Exploratory analysis of general health outcome measured by time from extubation to hospital discharge (days).	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Other	Effectiveness of Phagenyx® treatment on days on antimicrobials post-extubation (while in ICU)	Exploratory analysis of general health outcome measured by days on antimicrobials post-extubation (while in ICU).	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Other	Effectiveness of Phagenyx® treatment on hospital discharge destination	Exploratory analysis of general health outcome measured by hospital discharge destination (home, home+care, nursing home, other hospital, rehabilitation centre).	Up to 90 days after the final Phagenyx® treatment
Other	Effectiveness of Phagenyx® treatment on ICU readmission rate during hospital stay	Exploratory analysis of general health outcome measured by ICU readmission rate during hospital stay.	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Other	Effectiveness of Phagenyx® treatment on tracheostomies per subgroup	Exploratory analysis of general health outcome measured by number of and reason for tracheostomies per subgroup after PES-treatment during hospital stay.	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Other	Effectiveness of Phagenyx® treatment on chest X-rays for suspected pneumonia.	Exploratory analysis of general health outcome measured by total number of chest X-rays during hospital stay after ICU discharge for suspected pneumonia.	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Primary	Effectiveness of Phagenyx® treatment in reducing severity of unsafe swallows - Penetration-Aspiration Scale (PAS) Scores	Analysis of a two endpoints composite (FS-statistic) on a hierarchy of clinical priorities: Endpoint 1 - Swallowing safety based on worst PAS score in up to 4 thin (water) boli for each patient during FEES assessment converted to a trichotomised ordinal response of safe (PAS 1-3), penetration (PAS 4-5), or aspiration (PAS 6-8).; The PAS provides a scoring system for airway closure and clearance during FEES. The PAS is a validated 8-point scale quantifying penetration and aspiration events primarily by the depth to which material passes into the airway and whether or not it is ejected.	Day 2 (~24 to ~60 hours) after the final Phagenyx® treatment
Primary	Effectiveness of Phagenyx® treatment in reducing the severity of unsafe swallows - Dysphagia Outcome and Severity Score (DOSS) score	Analysis of a two endpoints composite (FS-statistic) on a hierarchy of clinical priorities: Endpoint 2 - DOSS scale score determined by bedside assessment.; The DOSS is a simple, easy-to-use, 7-point scale developed to systematically rate the functional severity of dysphagia based on objective assessment and make recommendations for diet level, independence level, and type of nutrition.; Severe dysphagia; Moderately severe dysphagia; Moderate dysphagia; Mild-moderate dysphagia; Mild dysphagia; Functional limitation and modified independence; Normal in all situations	7±1 days after the final Phagenyx® treatment
Secondary	Effectiveness of Phagenyx® treatment in improving DOSS score.	Changes in nutritional management and severity of dysphagia as measured by the DOSS score.	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on time from to feeding tube removal.	Changes in nutritional management and severity of dysphagia as measured by time from randomisation to removal of feeding tube.	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on time to oral intake.	Changes in nutritional management and severity of dysphagia as measured by time to oral intake (if applicable).	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on total days of enteral feeding.	Changes in nutritional management and severity of dysphagia as measured by total days of enteral feeding.	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment in improving Functional Oral Intake Scale (FOIS) score.	Changes in nutritional management and severity of dysphagia as measured by the FOIS score.; The FOIS provides a scoring system to document the functional level of oral intake of food and liquid in patients with dysphagia. It is a validated 7-point ordinal scale easily completed from information contained in medical charts, dietary journals, and/or patient reports.; Nothing by mouth; Tube dependent with minimal attempts of food or liquid; Tube dependent with consistent intake of liquid or food; Total oral diet of a single consistency; Total oral diet with multiple consistencies but requiring special preparation or compensations; Total oral diet with multiple consistencies without special preparation, but with specific food limitations; Total oral diet with no restriction	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment in improving Dysphagia Severity Rating Scale (DSRS) score.	Changes in nutritional management and severity of dysphagia as measured by the DSRS score.; The DSRS is a simple to use, validated 13-point scale composed of a 3-component score that includes feeding independence, but nutrition level and diet modification is split into the components of liquid feeding and overall diet consistency. The DSRS is the sum of the scores of each of the 3 individual components (range 0-4 for each component) rather than a combination of the three components into an ordinal scale.; Best score = 0 (no dysphagia) Worst score = 12 (NPO)	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on time from extubation to ICU discharge	General health outcome measured by time from extubation to ICU discharge (days).	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on length of stay in ICU	General health outcome measured by length of stay in ICU (days).	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on length of stay in hospital.	General health outcome measured by length of stay in hospital (days).	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on number of patients with re-intubation during hospital stay	General health outcome measured by number of patients with re-intubation during hospital stay.	Up to 14 ± 1 days after the final Phagenyx® treatment (or hospital discharge if earlier).
Secondary	Effectiveness of Phagenyx® treatment on mortality	General health outcome measured by 30-day and 90-day mortality.	Up to 90 days after completion of the final Phagenyx® treatment.

External Links

•   PhINEST Study - Protocol Manuscript